Avalyn Pharma completes target enrollment in MIST trial
Summary
Avalyn Pharma says it has completed target enrollment in its MIST trial. The update centers on clinical progress rather than any software product or corporate transaction. This is relevant to the life sciences sector because it reflects activity inside a pharma company. The item does not indicate an immediate commercial software buying event, but it does signal ongoing operational execution in clinical development.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected